Proactive text messaging (GetReady2Quit) and nicotine replacement therapy to promote smoking cessation among smokers in primary care: A pilot randomized trial protocol.


Journal

Contemporary clinical trials
ISSN: 1559-2030
Titre abrégé: Contemp Clin Trials
Pays: United States
ID NLM: 101242342

Informations de publication

Date de publication:
05 2019
Historique:
received: 25 10 2018
revised: 12 03 2019
accepted: 14 03 2019
pubmed: 30 3 2019
medline: 1 8 2020
entrez: 30 3 2019
Statut: ppublish

Résumé

Most smokers see a physician each year, but few use any assistance when they try to quit. Text messaging programs improve smoking cessation in community and school settings; however, their efficacy in a primary care setting is unclear. The current trial assesses the feasibility and preliminary clinical outcomes of text messaging and mailed nicotine replacement therapy (NRT) among smokers in primary care. In this single-center pilot randomized trial, eligible smokers in primary care are offered brief advice by phone and randomly assigned to one of four interventions: (1) Brief advice only, (2) text messages targeted to primary care patients and tailored to quit readiness, (3) a 2-week supply of nicotine patches and/or lozenges (NRT), and (4) both text messaging and NRT. Randomization is stratified by practice and intention to quit. The text messages (up to 5/day) encourage those not ready to quit to practice a quit attempt, assist those with a quit date through a quit attempt, and promote NRT use. The 2-week supply of NRT is mailed to patients' homes. Feasibility outcomes include recruitment rates, study retention, and treatment adherence. Clinical outcomes are assessed at 1, 2, 6, and 12-weeks post-enrollment. The primary outcome is ≥1self-reported quit attempt(s). Secondary clinical outcomes include self-reported past 7- and 30-day abstinence, days not smoked, NRT adherence, and exhaled carbon monoxide. This pilot assesses text messaging plus NRT, as a proactively offered intervention for smoking cessation support in smokers receiving primary care and will inform full-scale randomized trial planning. ClinicalTrials.govNCT03174158.

Identifiants

pubmed: 30923022
pii: S1551-7144(18)30624-4
doi: 10.1016/j.cct.2019.03.006
pmc: PMC6571033
mid: NIHMS1526394
pii:
doi:

Substances chimiques

Smoking Cessation Agents 0

Banques de données

ClinicalTrials.gov
['NCT03174158']

Types de publication

Clinical Trial Protocol Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

48-54

Subventions

Organisme : NIDA NIH HHS
ID : K23 DA038717
Pays : United States
Organisme : NIMH NIH HHS
ID : K24 MH114732
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Références

Nicotine Tob Res. 2004 Dec;6 Suppl 3:S303-10
pubmed: 15799593
Addiction. 2005 Feb;100(2):257-8
pubmed: 15679756
Nicotine Tob Res. 2017 Aug 1;19(8):901-907
pubmed: 27838659
Arch Intern Med. 2010 Jul 12;170(13):1155-60
pubmed: 20625025
Health Aff (Millwood). 2010 Jun;29(6):1214-9
pubmed: 20530358
Patient Educ Couns. 2014 Feb;94(2):261-8
pubmed: 24321403
J Hosp Med. 2018 Jan 25;13(7):488-489
pubmed: 29370320
MMWR Morb Mortal Wkly Rep. 2011 Nov 11;60(44):1513-9
pubmed: 22071589
Addiction. 2008 Mar;103(3):478-84; discussion 485-6
pubmed: 18269367
Addiction. 2005 Mar;100(3):299-303
pubmed: 15733243
JMIR Mhealth Uhealth. 2016 May 20;4(2):e49
pubmed: 27207211
JMIR Form Res. 2018 Jan-Jun;2(1):
pubmed: 30506038
JMIR Mhealth Uhealth. 2019 Mar 26;7(3):e11498
pubmed: 30912755
Addiction. 2008 Jun;103(6):998-1006; discussion 1007-8
pubmed: 18422823
JMIR Mhealth Uhealth. 2018 Aug 31;6(8):e173
pubmed: 30170994
Obstet Gynecol. 2012 Jan;119(1):14-20
pubmed: 22143257
MMWR Morb Mortal Wkly Rep. 2009 Nov 13;58(44):1227-32
pubmed: 19910909
JAMA Intern Med. 2016 Mar;176(3):340-9
pubmed: 26831740
Addiction. 2008 Aug;103(8):1371-8
pubmed: 18855827
Am J Manag Care. 2013 Jul;19(7):554-61
pubmed: 23919419
J Health Commun. 2018;23(4):370-378
pubmed: 29578832
Eur J Cardiovasc Prev Rehabil. 2006 Dec;13(6):931-7
pubmed: 17143125
Addiction. 2014 Jul;109(7):1184-93
pubmed: 24661312
Psychosomatics. 2009 Nov-Dec;50(6):613-21
pubmed: 19996233
J Behav Med. 2005 Apr;28(2):139-47
pubmed: 15957569
Health Technol Assess. 2012;16(38):1-205, iii-v
pubmed: 23046909
Addict Behav. 2011 Jul;36(7):713-6
pubmed: 21371825
Am J Prev Med. 2011 Nov;41(5):498-503
pubmed: 22011421
JAMA Intern Med. 2015 Feb;175(2):218-26
pubmed: 25506771
Psychiatry Res. 2012 Dec 30;200(2-3):89-95
pubmed: 22901437
MMWR Morb Mortal Wkly Rep. 2018 Jan 19;67(2):53-59
pubmed: 29346338
Cochrane Database Syst Rev. 2012 Mar 14;(3):CD009756
pubmed: 22419345
Nicotine Tob Res. 2011 May;13(5):361-8
pubmed: 21350041
Arch Intern Med. 2011 Nov 28;171(21):1901-7
pubmed: 22123796
Clin Ther. 2008 Oct;30(10):1852-8
pubmed: 19014840
Addiction. 2008 Jun;103(6):1039-47
pubmed: 18373724
Cochrane Database Syst Rev. 2009 Oct 07;(4):CD006611
pubmed: 19821377
BMJ. 2000 Jan 8;320(7227):114-6
pubmed: 10625273
Lancet. 2011 Jul 2;378(9785):49-55
pubmed: 21722952
J Gen Intern Med. 2009 Jul;24(7):783-8
pubmed: 19247718
Health Psychol. 1991;10(5):360-5
pubmed: 1935872
AIDS. 2006 Jan 9;20(2):253-60
pubmed: 16511419
AIDS Behav. 2017 Jul;21(7):1964-1974
pubmed: 27605365
Br J Addict. 1991 Sep;86(9):1119-27
pubmed: 1932883
J Natl Cancer Inst Monogr. 2013 Dec;2013(47):199-205
pubmed: 24395992
Am J Prev Med. 2005 Jan;28(1):119-22
pubmed: 15626567
Am J Prev Med. 2014 Sep;47(3):242-50
pubmed: 24913220
Nicotine Tob Res. 2016 Mar;18(3):314-20
pubmed: 25795658
MMWR Morb Mortal Wkly Rep. 2002 Jul 26;51(29):642-5
pubmed: 12186222
Am J Prev Med. 2008 Mar;34(3):212-5
pubmed: 18312809
Tob Control. 2017 Nov;26(6):683-689
pubmed: 27852892
Am J Prev Med. 2018 May;54(5):620-629
pubmed: 29551324
JAMA Intern Med. 2014 May;174(5):671-7
pubmed: 24615217
J Fam Pract. 1992 Jan;34(1):61-5
pubmed: 1728656
Health Psychol. 2006 Jul;25(4):462-73
pubmed: 16846321
Addiction. 2014 Jan;109(1):35-43
pubmed: 23919621
Addict Behav. 2014 May;39(5):907-17
pubmed: 24462528
J Am Coll Health. 2008 Sep-Oct;57(2):245-8
pubmed: 18809542
Nicotine Tob Res. 2002 May;4(2):149-59
pubmed: 12028847
Psychopharmacology (Berl). 2005 Feb;177(4):400-8
pubmed: 15289997
J Health Commun. 2012;17 Suppl 1:44-53
pubmed: 22548598
J Subst Abuse Treat. 2015 Sep;56:1-10
pubmed: 25720333
JAMA. 2015 Sep 22-29;314(12):1255-63
pubmed: 26393848
Nicotine Tob Res. 2018 Sep 4;20(10):1163-1172
pubmed: 29059394
J Gen Intern Med. 2006 Sep;21(9):973-8
pubmed: 16918744
J Am Coll Health. 2004 Sep-Oct;53(2):71-8
pubmed: 15495883
Nicotine Tob Res. 2009 Apr;11(4):408-17
pubmed: 19325134

Auteurs

G R Kruse (GR)

Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Tobacco Research and Treatment Center, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA. Electronic address: gkruse@mgh.harvard.edu.

E Park (E)

Tobacco Research and Treatment Center, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA; Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA.

J E Haberer (JE)

Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA; Center for Global Health, Massachusetts General Hospital, Boston, Massachusetts, USA.

L Abroms (L)

Department of Prevention and Community Health, Milken Institute School of Public Health, George Washington University, Washington, DC, USA.

N N Shahid (NN)

Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

S E Howard (SE)

Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

Y Chang (Y)

Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

J S Haas (JS)

Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.

N A Rigotti (NA)

Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Tobacco Research and Treatment Center, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH